Cephalon: Clinical Trials

148 trials sponsored by Cephalon, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

113 completed, 26 terminated, 5 withdrawn, 4 unknown. 64 Phase 2, 47 Phase 3, 25 Phase 1, 13 Phase 4, 6 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 264Completed 43, Terminated 16, Withdrawn 3, Unknown 2
Phase 347Completed 42, Terminated 4, Withdrawn 1
Phase 125Completed 17, Terminated 7, Unknown 1
Phase 413Completed 11, Terminated 1, Unknown 1
Not applicable6Completed 3, Terminated 1, Unknown 1, Withdrawn 1
Early Phase 11Completed 1

Follow Cephalon: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
Bendamustine, Dexamethasone - AL Amyloidosis
Phase 2CompletedColumbia University402013-01-012020-03-30
Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy
Bendamustine, Ofatumumab - Diffuse Large B-Cell Lymphoma
Phase 2CompletedSCRI Development Innovations, LLC222012-10-012017-11-22
Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer
Obatoclax Mesylate, Carboplatine and Etoposide, Carboplatin and Etoposide - Extensive-stage Small Cell Lung Cancer
Phase 3WithdrawnCephalon2012-08-012012-08-15
A Study to Assess the Abuse Potential of Hydrocodone Extended-Release Tablet in Recreational Opioid Users
45-mg hydrocodone bitartrate extended-release tablet (crushed or intact), Placebo - Drug Abuse
Phase 1CompletedCephalon1002012-03-012012-11-21
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
Bendamustine, Bortezomib - Multiple Myeloma
Phase 2TerminatedNYU Langone Health242011-09-012018-02-07
Study of Arsenic Trioxide in Small Cell Lung Cancer
Arsenic Trioxide - Lung Cancer, Cancer of Lung
Phase 2CompletedEmory University202011-08-012021-02-17
Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Omacetaxine, Cytarabine - Leukemia
Phase 2CompletedM.D. Anderson Cancer Center362011-07-012018-05-30
Effentora® in Clinical Practice - a Non-interventional Study to Evaluate Satisfaction and Tolerability
Effentora® - Cancer, Pain
CompletedCephalon6002011-07-012012-10-24
A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer
Trastuzumab, Docetaxel, Trastuzumab, Docetaxel, Bevacizumab, Trastuzumab+Docetaxel+NPLD - Breast Cancer
Phase 2CompletedAustrian Breast & Colorectal Cancer Study Group1002011-06-012014-05-13
Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma
CEP-9722, Gemcitabine, Cisplatin - Solid Tumors or Mantle Cell Lymphoma
Phase 1CompletedCephalon242011-05-012013-01-18
Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients
Placebo, Armodafinil - Chronic Myeloid Leukemia
Not applicableTerminatedM.D. Anderson Cancer Center12011-05-012015-12-08
A Study to Evaluate the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Hepatic Function and Subjects With Moderate Hepatic Impairment
Hydrocodone bitartrate extended-release tablet - Hepatic Impairment
Phase 1CompletedCephalon162011-04-012012-04-24
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Armodafinil, Placebo - Depression
Phase 3CompletedCephalon3992011-03-012016-05-26
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Bendamustine, Rituximab - Diffuse Large B-Cell Lymphoma, Lymphoma, Diffuse Large-Cell
Phase 2CompletedUNC Lineberger Comprehensive Cancer Center232011-03-012017-05-24
A Study to Assess the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Renal Function and Subjects With Varying Degrees of Renal Impairment
Hydrocodone Bitartrate extended-release tablet - Renal Impairment
Phase 1CompletedCephalon552011-03-012012-04-24
Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies
Armodafinil - Parkinsons Disease, Lewy Bodies Disease
Not applicableWithdrawnNYU Langone Health2011-01-012021-08-23
Study to Evaluate the Safety and Efficacy of Placulumab (CEP-37247) Administered by the Transforaminal Epidural Route for the Treatment of Patients With Lumbosacral Radicular Pain Associated With Disk Herniation
CEP-37247, Placebo - Sciatica
Phase 1 / Phase 2CompletedCephalon982011-01-012016-07-21
Nuvigil or Placebo in Newly Diagnosed Malignant Glioma
Nuvigil®, Placebo - Malignant Glioma
Phase 2TerminatedH. Lee Moffitt Cancer Center and Research Institute62010-12-012013-12-16
Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma
Bendamustine, Rituximab, Y-90 ibritumomab - Lymphoma, Follicular
Phase 2CompletedDartmouth-Hitchcock Medical Center392010-10-012021-05-18
Single Ascending-Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women
CEP-37251, Placebo - Bone Loss, Osteoporosis
Phase 1TerminatedCephalon22010-07-012014-05-12

Showing 20 of 148. Sign in to see all of them.

Conditions studied

Disorders of Excessive Somnolence (15)  ·  Neoplasms (13)  ·  Lymphoma, Non-Hodgkin (12)  ·  Fatigue (10)  ·  Lymphoma (9)  ·  Leukemia (8)  ·  Multiple Myeloma (8)  ·  Pain (8)  ·  Sleep Apnea, Obstructive (8)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (7)  ·  Narcolepsy (7)  ·  Breakthrough Pain (6)  ·  Depression (6)  ·  Schizophrenia (6)  ·  Breast Neoplasms (5)

Interventions

Modafinil (46)  ·  Bendamustine Hydrochloride (31)  ·  Rituximab (13)  ·  Arsenic Trioxide (12)  ·  Bortezomib (7)  ·  lestaurtinib (7)  ·  Tiagabine (6)  ·  Fentanyl (5)  ·  ofatumumab (5)  ·  Ascorbic Acid (4)  ·  Docetaxel (4)  ·  Cytarabine (3)  ·  Dexamethasone (3)  ·  Doxorubicin (3)  ·  Homoharringtonine (3)

Countries

United States (124)  ·  Canada (24)  ·  Germany (10)  ·  France (9)  ·  Poland (9)  ·  Australia (8)  ·  Italy (7)  ·  Hungary (6)  ·  Puerto Rico (6)  ·  Spain (6)  ·  United Kingdom (6)  ·  Bulgaria (5)  ·  Ukraine (4)  ·  Argentina (3)  ·  India (3)

Top investigators

Gwendolyn Neibler, DO (2)  ·  Jorge Cortes, MD (2)  ·  Laurence J. van Warmerdam, MD, PhD (2)  ·  Mark Kirschbaum, MD (2)  ·  Philip T Ninan, MD (2)  ·  Amitabha Mazumder, MD (1)  ·  Andreas Hochhaus, MD Prof Dr (1)  ·  Apostolia M. Tsimberidou, MD, PhD (1)  ·  Bradley F Boeve, MD (1)  ·  Bruce Cheson, MD (1)  ·  Bruce D Cheson, MD (1)  ·  Carlos de Castro, MD (1)  ·  Carmen Escalante, MD (1)

Results publications

PMID 10080589, PMID 10561296, PMID 10628376, PMID 10766175, PMID 11230490, PMID 11745247, PMID 12138395, PMID 12907602, PMID 1304367, PMID 15383473, PMID 15934498, PMID 16539726, PMID 17679724, PMID 17881719, PMID 18413464, PMID 18572266, PMID 19029516, PMID 19074216, PMID 19689921, PMID 19880686, PMID 20008298, PMID 20051221, PMID 20175410, PMID 20185313, PMID 20530317, PMID 20603435, PMID 20673554, PMID 20816042, PMID 21239695, PMID 21270442, PMID 21641776, PMID 21815182, PMID 21957829, PMID 22104981, PMID 22178084, PMID 22451423, PMID 22687392, PMID 22837377, PMID 22896000, PMID 23248254, PMID 23251870, PMID 23468307, PMID 23855816, PMID 23955074, PMID 24532997, PMID 2470152, PMID 24903629, PMID 2491964, PMID 24925211, PMID 24997137

NIH funding

2009 (4), 2008 (1), F32MH075583 (1), K23CA164015 (1), P30CA008748 (1), P50AG016574 (1), R01AG015866 (1), R01HL076101 (1), R01NS042759 (1)